
Loading, please wait...

Loading, please wait...

This randomized, placebo-controlled trial evaluated whether personalizing accelerated intermittent theta-burst stimulation (aiTBS) using resting-state fMRI connectivity and EEG-derived stimulation frequency could improve outcomes in treatment-resistant depression. Fifty-one patients were randomized to fMRI-connectivity-guided aiTBS, combined fMRI/EEG-guided aiTBS, or sham; 43 completed the protocol. Participants received 10 sessions daily for 5 consecutive days. Neither active treatment significantly outperformed sham for the primary MADRS outcome at 1 week or secondary DARS anhedonia scores. Response and remission rates also did not differ significantly between groups. The findings suggest that individualized targeting and frequency selection did not provide additional antidepressant benefit over sham in this trial, highlighting the need for further adequately powered studies.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


This randomized, placebo-controlled trial evaluated whether personalizing accelerated intermittent theta-burst stimulation (aiTBS) using resting-state fMRI connectivity and EEG-derived stimulation frequency could improve outcomes in treatment-resistant depression. Fifty-one patients were randomized to fMRI-connectivity-guided aiTBS, combined fMRI/EEG-guided aiTBS, or sham; 43 completed the protocol. Participants received 10 sessions daily for 5 consecutive days. Neither active treatment significantly outperformed sham for the primary MADRS outcome at 1 week or secondary DARS anhedonia scores. Response and remission rates also did not differ significantly between groups. The findings suggest that individualized targeting and frequency selection did not provide additional antidepressant benefit over sham in this trial, highlighting the need for further adequately powered studies.
2 months ago

Researchers have identified compound 8g, an orally bioavailable corydamine derivative that targets glutathione reductase. By dismantling redox defenses and disrupting NADPH homeostasis, 8g acts synergistically with sorafenib to trigger apoptosis and overcome drug resistance in hepatocellular carcinoma models.
Yesterday

A breakthrough blood test measuring the RNA biomarker Tu-Stroma detects microscopic serous tubal intraepithelial carcinoma (STIC) lesions with remarkable accuracy. This non-invasive diagnostic tool offers crucial biological insight to guide prophylactic surgery decisions for women carrying high-risk genetic mutations.
2 days back

Researchers have engineered novel light-on photoswitchable adrenoceptor agonists targeting β1-receptors. By remaining inactive until illuminated, these precision molecules offer reversible optical control, tailored relaxation kinetics, and distinct efficacy profiles, paving the way for targeted cardiovascular therapies.
Yesterday

A single-cell transcriptomic atlas reveals how peripheral nerve injuries cause dorsal root ganglion remodeling. By evaluating proximal nerve crush and resection, researchers identify distinct glial and immune programs that resolve neuropathic pain and promote regeneration.
3 weeks back

A breakthrough study demonstrates that fullerol-primed extracellular vesicles generated in a 3D SECCS bioreactor attenuate ferroptosis and restore myogenic regeneration in diabetes via the FOXO3 pathway, offering a cell-free therapeutic strategy for diabetic musculoskeletal degeneration.
3 weeks back